______________________________________________________________________________________________________________________________________________________________________________________________________
Gouttefangeas C, Rammensee HG. Personalized cancer vaccines: adjuvants are important, too. Review in Cancer Immunol Immunother 2018, Apr 11. doi: 10.1007/s00262-018-2158-4. [Epub ahead of print]
Dimitrov S, Gouttefangeas C, Besedovsky L, Jensen ATR, Chandran PA, Rusch E, Businger R, Schindler M, Lange T, Born J, Rammensee HG. Activated integrins identify functional antigen-specific CD8+ T cells within minutes after antigen stimulation. Proc Natl Acad Sci U S A 2018;115:E5536-E5545
Eckert F, Schaedle P, Zip D, Schmid-Horch B, Rammensee HG, Gani C, Gouttefangeas C. Impact of curative radiotherapy on the immune status of patients with localized prostate cancer. Oncoimmunology 2018, Online 27 Aug
Chandran PA, Heidu S, Zelba H, Schmid-Horch B, Rammensee HG, Pascolo S, Gouttefangeas C. A Simple and Rapid Method for Quality Control of Major Histocompatibility Complex-Peptide Monomers by Flow Cytometry. Front Immunol 2017;8:96
Löffler MW, Chandran PA, Laske K, Schroeder C, Bonzheim I, Walzer M, Hilke FJ, Trautwein N, Kowalewski DJ, Schuster H, Günder M, Carcamo Yañez VA, Mohr C, Sturm M, Nguyen HP, Riess O, Bauer P, Nahnsen S, Nadalin S, Zieker D, Glatzle J, Thiel K, Schneiderhan-Marra N, Clasen S, Bösmüller H, Fend F, Kohlbacher O, Gouttefangeas C, Stevanović S, Königsrainer A, Rammensee HG. Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. J Hepatol. 2016;65:849-55
Kvistborg P*, Gouttefangeas C*, Aghaeepour N, Cazaly A, Chattopadhyay PK, Chan C, Eckl J, Finak G, Hadrup SR, Maecker HT, Maurer D, Mosmann T, Qiu P, Scheuermann RH, Welters MJP, Ferrari G, Brinkman RR, Britten CM. Thinking outside the gate: single-cell assessments in multiple dimensions. Letter in Immunity 2015, 42:591-2. * Contributed equally.
Britten CM, van der Burg SH, Gouttefangeas C. A framework for T cell assays. Editorial in Oncotarget 2015;6:35143-4
Gouttefangeas C, Walter S, M.J.P. Welters MJP, Ottensmeier C, Sjoerd H.van der Burg S.H. Britten CM, Chan C. Chan. Flow Cytometry in Cancer Immunotherapy: Applications, Quality Assurance, and Future. Book chapter in Cancer Immunology: Translational Medicine from Bench to Bedside, Ed Springer, 2014
Widenmeyer M, Griesemann H, Stevanović S, Feyerabend S, Klein R, Attig S, Hennenlotter J, Wernet D, Kuprash DV, Sazykin AY, Pascolo S, Stenzl A, Gouttefangeas C, Rammensee HG. Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients. Int J Cancer 2012;131:140-149
Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJM, O’Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff THM, Ottensmeier C, Pawelec G, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. Immunity 2012;37:1-2
Attig S, Hennenlotter J, Pawelec G, Klein G, Koch S, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, Gouttefangeas C. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. Cancer Res 2009;69:8412-8419
Feyerabend S, Stevanovic S, Gouttefangeas C, Wernet D, Hennenlotter J, Bedke J, Dietz K, Pascolo S, Kuczyk M, Rammensee HG, Stenzl A. Novel multi-peptide vaccination in HLA-A2+ hormone sensitive patients with biochemical relapse of prostate cancer. Prostate 2009;69:917-927
Britten CM*, Gouttefangeas C*, Schoenmaekers-Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Müller-Berghaus J, Haas I, Mackensen A, Køllgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanović S, Wölfel T, van der Burg SH. The CIMT-Monitoring panel: A two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays. Cancer Immunol Immunother 2008;57:289-302. * Contributed equally.